CARMAT's Aeson device gains momentum in Europe as a bridge-to-transplant solution

This post was originally published on News-medical.net

You will shortly be re-directed to the publisher's website

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “CARMAT”), provides an update on Aeson® artificial heart’s uptake as a bridge to transplant in Europe.